# Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

> **NCT04767698** · PHASE2 · TERMINATED · sponsor: **Johns Hopkins University** · enrollment: 4 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Short-course Ocrelizumab
- **DRUG:** Continued Ocrelizumab

## Key facts

- **NCT ID:** NCT04767698
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-05-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The funding source decided to stop funding the study.
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767698, "Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04767698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*